ClearStar Inc - US-based background and medical screening provider - Too early to estimate the impact of Covid-19 on 2020. Increasingly optimistic that virus impact will not be as bad as feared. Not yet returned to pre-Covid-19 revenue run rate, but increase in sales so far extremely encouraging. Secured a contract in May with bluechip customer that provides technology testing and industrial automation. Awarded a contract by a real estate rental company to provide tenant screening. Benefiting from cost mitigation measures. Net debt of USD1.5 million and USD2.1 million of available funds as of Monday.
Current stock price: 40.00 pence
Year-to-date change: down 23%
By Tapan Panchal; tapanpanchal@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
